Library

X
feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Electronic Resource
    Electronic Resource
    Monoclonal antibodies in imaging and therapy of colorectal cancer (1991)
    Springer
    World journal of surgery 15 (1991), S. 617-622 
    Details
    ISSN: 1432-2323
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Résumé Grâce aux anticorps monoclonaux marqués et le détecteur gamma Néoprobe, on a évalué la résecabilité et décelé des formations tumorales non palpables ou déterminé les marges de sécurité après résection des cancers colorectaux chez 84% de nos patients. Une tumeur occulte a été identifiée chez 18% des patients et a fait changer l'attitude thérapeutique chez 43% d'entre eux. L'utilisation des anticorps monoclonaux marqués offre des espoirs nouveaux dans 1'imagerie; la chirurgie radioguidée est une nouvelle voie de modalité thérapeutique.
    Abstract: Resumen La exploración intraoperatoria con instrumentos como el detector gamma Neoprobe ha sido de utilidad en el proceso de decisión quirúrgica en relación a la resecabilidad, a la detección de tumor adicional no fácilmente detectable mediante la palpación y la inspección, y en la determinación de los márgenes quirúrgicos. La identificación del tumor ha sido posible en 84% de los pacientes. Tumor oculto ha sido detectado en 18% de los pacientes valorables y modificó las decisiones quirúrgicas en 43%. Los nuevos anticuerpos monoclonales radiomarcados ofrecen la esperanza de nuevas posibilidades para imagenología, cirugía radio-inmunodirigida y potenciales modalidades terapéuticas.
    Notes: Abstract Intraoperative detection of colorectal carcinoma with the Neoprobe gamma detector has been useful in surgical decisionmaking regarding resectability by localizing additional tumor not readily identified by palpation or inspection, and in determining surgical resection margins. Tumor labeling has been achieved in 84% of the patients. Occult tumor has been identified in 18% of evaluable patients and changed operative decisions in 43% of patients. New monoclonal antibodies with radiolabels offer hope for more effective agents for imaging, Radioimmunoguided Surgery® and potential therapeutic modalities.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01789208
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 2
    Electronic Resource
    Electronic Resource
    Western blotting and isoform analysis of cathepsin D from normal and malignant human breast cell lines (1995)
    Springer
    Breast cancer research and treatment 35 (1995), S. 211-220 
    Details
    ISSN: 1573-7217
    Keywords: breast cancer ; cathepsin D isoforms ; Hs578Bst cells ; MCF7 cells ; MDA-MB-231 cells
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary Cathepsin D from normal (Hs578Bst) and malignant (MCF7, MDA-MB-231) breast cell lines has been characterized with regard to its kinetic properties, activity levels, precursor and processed Mr forms, and isoform composition. Normal cell cathepsin D appears to have a more neutral pH optimum (pH 3.5) than the cancer cell line (pH 3.0–3.2) and greater activity between pH values of 4.0 to 4.5. The two cancer cell lines have approximately 1.5 to 2.0-fold increased total acid protease activity and 2 to 3-fold increased pepstatin-inhibitable protease activity (i.e. cathepsin D) when compared to the normal breast cell line. Western blotting indicates that a major processed form of cathepsin D for all three cell lines occurs at 31 kDa. The cancer cell lines contain significant amounts of cathepsin D precursors of 47 and 42 kDa whereas the normal cell line contains little if any of these precursors. Isoelectric focusing indicates that the normal cell line contains approximately 50% of its total acid protease activity at pIs above 4 whereas the cancer cell lines contain 70–80% of their protease activity at such pIs. In addition, the cancer cell lines contain two to three major isoforms between pIs of 5.5 and 6.3 which were not present in the normal cell line. The isoforms from pI values of 5.5 to 7.3 for all three cell lines are 100% pepstatin-inhibitable. In addition, Western blot analysis indicates that these isoforms contain the processed 31 kDa form of cathepsin D. The combined results indicate that the two breast cancer cell lines are similar to biopsied malignant breast tissue in exhibiting altered acid protease isoform profiles with increased relative amounts of pepstatin-inhibitable and immunoreactive acid protease activity (cathepsin D) compared to normal breast tissue or cells.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00668211
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 3
    Electronic Resource
    Electronic Resource
    Analysis of cathepsin D in human breast cancer: Usefulness of the processsed 31 kDa active form of the enzyme as a prognostic indicator in node-negative and node-positive patients (2000)
    Springer
    Breast cancer research and treatment 60 (2000), S. 173-179 
    Details
    ISSN: 1573-7217
    Keywords: active processed cathepsin D ; breast cancer ; prognostic indicator ; survival analysis
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract The relative amounts of the precursor (52 kDa) and processed (31,27 kDa) forms of cathepsin D have been analyzed by Western blotting in biopsied breast tissue cytosols from 134 lesions from invasive breast cancer patients, 24 lesions from patients with ductal carcinoma in situ (DCIS), 227 lesions from benign breast disease patients, and 28 lesions from normal control subjects. The mean relative percentage amount of the 31 kDa form was significantly increased (p〈0.001) in the invasive breast cancer group compared to the other three groups. In addition, the mean relative percentage amount of the 31 kDa form was significantly increased (p〈0.05) in node-positive compared to node-negative breast cancer patients. In the benign breast disease group, patients with proliferative-type disease had a significantly increased (p=0.02) mean relative percentage amount of the 31 kDa form of cathepsin D compared to patients with nonproliferative-type disease. Invasive breast cancer patients were followed for up to 75 months to determine if the relative percentage amount of the 31 kDa form of cathepsin D was predictive of disease-free and overall survival. Although the amount of the 31 kDa form was not predictive of disease-free survival, patients in the ‘high’ 31 kDa group (〉18) were significantly (p〈0.05) more likely to die than patients in the ‘low’ 31 kDa group (≤18%). The 12 patients who died were all node-positive and in the high 31 kDa group. It thus appears that the relative amount of the processed, active 31 kDa form of cathepsin D is a useful prognostic indicator, at least in node-positive breast cancer patients.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1023/A:1006394401199
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...